Gensight Biologics Equity 2024

Gensight Biologics Aktienanalyse

What does Gensight Biologics do?

Gensight Biologics SA is a biotechnology company specializing in the development of gene therapies for genetically inherited eye diseases. The company is based in Paris, France, with offices in Amsterdam and New York. The company's history began in 2012 when the founder, Bernard Gilly, had the idea to develop gene therapy for liver diseases. After several years of research and development, it became clear that the company could not develop a commercially viable solution due to the complexity of liver diseases and the high treatment costs. In 2013, the company shifted its focus to the development of gene therapies for genetically inherited eye diseases. Since then, Gensight Biologics SA has conducted several studies and clinical trials and is now a leading provider in this market segment. Gensight Biologics SA's business model is based on the development of gene therapies aimed at correcting the genetic defect and repairing the corresponding cells in the eye. The gene therapy is conducted using adeno-associated viruses (AAV), which introduce a normal gene into the diseased tissue. Gensight Biologics' particular focus is on the development of gene therapies for the treatment of eye diseases, with a focus on the research and treatment of rare diseases. The company has two central product lines. Firstly, it offers gene therapies targeting genetically inherited eye diseases such as retinitis pigmentosa (RP). This disease is inherited and leads to gradual loss of vision and, in severe cases, blindness. Gene therapy aims to repair the responsible gene and improve cell function and vision. Secondly, Gensight Biologics SA offers gene therapies targeting liver diseases such as Wilson's disease and gout, where copper and uric acid, respectively, are not properly metabolized. Here, gene therapy aims to repair the corresponding gene and reduce disease-related functional impairments. Gensight Biologics SA works closely with regulatory authorities and clinical partners to ensure the safety and efficacy of their gene therapies. The therapies are currently being tested in clinical trials to assess their effectiveness and safety. Gensight Biologics SA also collaborates with some of the world's leading doctors and researchers in the field of ophthalmology. While Gensight Biologics SA's gene therapies are still in the development phase, the clinical trials have shown promising results, and the company expects their therapies to be approved soon. The company follows a well-thought-out growth model and plans to develop further products for the treatment of eye diseases in the future. Overall, Gensight Biologics SA is a biotechnology company specialized in gene therapies, with a focus on researching and treating rare eye diseases. The company presents a promising investment option due to its innovative product range, close collaboration with researchers and clinical partners, and solid growth strategy. Gensight Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Gensight Biologics's Equity

Gensight Biologics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Gensight Biologics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Gensight Biologics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Gensight Biologics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Gensight Biologics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Gensight Biologics Stock

What is the equity of Gensight Biologics this year?

Gensight Biologics has equity of -30.7 M EUR this year.

What was the equity of Gensight Biologics compared to the previous year?

The equity of Gensight Biologics has increased/decreased by 100.94% increased compared to the previous year.

What impact does a high equity have on investors of Gensight Biologics?

A high equity is advantageous for investors of Gensight Biologics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Gensight Biologics?

A low equity can be a risk for investors of Gensight Biologics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Gensight Biologics affect the company?

An increase in equity of Gensight Biologics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Gensight Biologics affect the company?

A reduction in equity of Gensight Biologics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Gensight Biologics?

Some factors that can affect the equity of Gensight Biologics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Gensight Biologics so important for investors?

The equity of Gensight Biologics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Gensight Biologics take to change the equity?

To change equity, Gensight Biologics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Gensight Biologics pay?

Over the past 12 months, Gensight Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gensight Biologics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Gensight Biologics?

The current dividend yield of Gensight Biologics is .

When does Gensight Biologics pay dividends?

Gensight Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gensight Biologics?

Gensight Biologics paid dividends every year for the past 0 years.

What is the dividend of Gensight Biologics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gensight Biologics located?

Gensight Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gensight Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gensight Biologics from 7/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did Gensight Biologics pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Gensight Biologics in the year 2023?

In the year 2023, Gensight Biologics distributed 0 EUR as dividends.

In which currency does Gensight Biologics pay out the dividend?

The dividends of Gensight Biologics are distributed in EUR.